Siemens Healthineers will rebrand its in vitro diagnostics business as Olyrian Diagnostics and run it as a standalone organization by mid-2028. The unit covers lab and point of care testing, lab automation and informatics, and makes more than 16 billion tests a year. It stays inside Siemens Healthineers through the transition, with products, contracts and service levels unchanged for now.
The parent drops the Siemens name and becomes Healthineers over a three year transition starting in 2027, paying Siemens 300 million euros for the change. Siemens plans to give up its controlling stake through a spin-off of Healthineers shares, with a shareholder vote at the February annual meeting. Sharon Bracken, who heads Diagnostics, called Olyrian the unit's next chapter.
Comparable diagnostics revenue fell 4.2 percent in the fourth quarter, with China still declining on what the CFO called a structural rebasing. The company targets another 400 million euros of savings at the unit, much of it by 2028, plus measures to offset more than 300 million euros of stranded costs. Group revenue was about 23.6 billion euros for the year ended September 30, across roughly 75,000 staff.
For diagnostics startups shopping a platform, the timeline is the part to read. A unit heading for separation usually has a narrow window for tuck-in deals, between the announcement and the point where carve-out accounting fixes the perimeter.